News and Trends 18 Jul 2019 Genmab’s Huge IPO Raises €450M to Develop Antibody Drugs The Danish biotech Genmab has made a big splash on the Nasdaq, raising a €450M ($506M) IPO to fuel its antibody drug programs in cancer, autoimmune diseases, and more. This… July 18, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 6 Jun 2019 Shares Drop 90% as Antibody for Inflammatory Skin Disease Fails Phase II …drug didn’t have any effect on the outcome. Hidradenitis suppurativa is a chronic disease that lasts for life and can be difficult to manage. InflaRx’s failed antibody was designed to… June 6, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jun 2019 Janssen and Genmab Team Up Again for Another Potential Cancer Blockbuster …needs for patients,” stated the CEO of Genmab, Jan van de Winkel. “Pre-clinical data suggest that [the candidate antibody] could be superior to daratumumab for certain tumor cell types and… June 11, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 11 Dec 2017 Belgian Antibody Proves Effective to Treat Myasthenia Gravis …Phase II trial with ARGX-113 (efgartigimod), in which the antibody therapy has proved to provide a significant improvement in patients with generalized myasthenia gravis, a form of the disease that… December 11, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jul 2017 Roche and Ireland’s Biggest Biopharma Take Their Parkinson’s Antibody to Phase II Prothena and Roche are advancing their Parkinson’s antibody to Phase II, triggering a new milestone payment from what is proving a lucrative deal for Prothena. Prothena, the largest biopharma in… July 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 26 Jul 2024 Confo Therapeutics raises $60 million to focus on agonistic GPCR antibodies …GLP1R antibodies. One notable candidate, TB59-2, has shown strong preclinical efficacy in controlling blood glucose levels with a favorable pharmacokinetic profile. Another candidate, TB01-3, demonstrated effective blood glucose regulation in… July 26, 2024 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 4 Apr 2023 BioNTech adds antibody-drug conjugates to cancer portfolio with potential $1.5B partnership deal BioNTech SE and Duality Biologics (Suzhou) Co. Ltd. have entered into exclusive license and collaboration agreements for two antibody-drug conjugate (ADC) assets to develop, manufacture and commercialize the two assets… April 4, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 May 2022 Tubulis Rides Investment Wave in ADCs with €60M Series B …drug-to-antibody ratio as well as the linker chemistry of the ADC,” said Schumacher. For example, ADCs with very toxic payloads should pack fewer molecules per antibody, whereas candidates with milder… May 3, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jan 2023 Hummingbird Bioscience and Synaffix to develop ADC program Synaffix B.V. and Hummingbird Bioscience have entered into a licensing agreement that will enable Hummingbird Bio to develop a next generation antibody drug conjugate (ADC) program using Synaffix technology. Synaffix… January 5, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 17 Oct 2017 Blockbuster Potential: How Biotech is Paving the Way to Clear Skin from Psoriasis …series of phase III trials with the antibody for psoriatic arthritis, as well as another head-to-head study with the anti-IL-17 antibody, Cosentyx. Boehringer Ingelheim and AbbVie have partnered to develop… October 17, 2017 - 7 minutesmins - By Diana Kwon Share WhatsApp Twitter Linkedin Email
In Depth 2 Apr 2025 Beyond amyloid: The search for the next big thing in Alzheimer’s treatment …the amyloid-plaques-targeting antibody showed some plaque clearance, the cognitive data were mixed at best. Then came Leqembi in 2023. This second-generation amyloid-targeting antibody showed a modest but statistically significant slowing… April 2, 2025 - 10 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 22 Aug 2025 The Sanofi pipeline in 2025: Is the play-to-win strategy working? …Sanofi acquires the full Vigil pre-clinical neurodegenerative pipeline. However, the TREM2 agonist antibody iluzanebart (VGL101), which Vigil had been developing for rare microgliopathies, was excluded from the acquisition, and rights… August 22, 2025 - 12 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email